AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2767907&ei=n4aaUvD9OdO60AGuJw&usg=AFQjCNEQEWrmbkpNId04vYe9N6j5Zpm80w
Amgen Inc Announces Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
Saturday, 1 Jun 2013 07:30am EDT
Amgen Inc announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The results will be presented as an oral presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract No. LBA9008). The study met its primary endpoint of durable response rate (DRR), defined as the rate of complete or partial response lasting continuously for at least six months. A statistically significant difference was observed in DRR with 16% in the talimogene laherparepvec arm versus 2% in the GM-CSF arm (95% CI, 12%-21%, versus 95% CI, 0%-5%, p
